Vol. 6 No. 6 (2026): June
Reimbursement Reviews

Finerenone (Kerendia)

decorative image of the issue cover

Published June 9, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses finerenone (Kerendia): 10 mg, 20 mg, or 40 mg oral tablets.
  • Indication: As an adjunct to standard of care in adults for the treatment of heart failure with left ventricular ejection fraction (LVEF) ≥40% to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits.